Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Hye Sook Han; Bum Jun Kim; Hee‐Jung Jee; Min-Hee Ryu; Se Hoon Park; Sun Young Rha; Jong Gwang Kim; Woo Kyun Bae; Keun‐Wook Lee; Do-Youn Oh; In Ho Kim; Sun Jin Sym; So Yeon Oh; Hyeong Su Kim; Ji-Hye Byun; Dong Sook Kim; Young Ju Suh; Hyonggin An; Dae Young Zang

doi:10.1177/17588359211042812

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Han et al. (2021) studied this question.

synapsesocial.com/papers/69dd59a70a7b4bc8c4101815 https://doi.org/10.1177/17588359211042812

View Full Paper

Ask AI

Bookmark

Share

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Ask about this paper

Abstract

Discussion

Cite This Study

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading